AstraZeneca's Saphnelo (anifrolumab) Receives MHLW's Approval for the Treatment of Systemic Lupus Erythematosus
Shots:
- The approval was based on the clinical program including two P-III TULIP & P-II MUSE trials evaluated the efficacy and safety of Saphnelo vs PBO in 362 & 305 patients with SLE who are receiving standard therapy
- The results showed a reduction in overall disease activity across organ systems- including skin and joints- and achieved a sustained reduction in OCS across both groups
- Saphnelo marks the first regulatory approval for a type I IFN receptor antagonist in Japan & has approved in the US for the same indication. The therapy is under regulatory review for SLE in the EU & company plans for an additional P-III trial for LN- CLE & myositis
| Ref: AstraZeneca | Image: Mint
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com